Start / Plenary Session – inactive due to federal service / 4 62 shine ibrutinib br vs br limitations to the trial

Plenary Session – inactive due to federal service

4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial

18 min • 4 juni 2022
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/

Senaste avsnitt

CABINET - trial - Cabozantinib for NET

20 februari | 19 min

CIA says lab leak, Fauci's pardon, NIH's meetings, RFK Jr's hearing & more!

19 februari | 39 min

Why the NIH is a broken funding system

19 februari | 32 min

Elon's 6 Engineers/ Unelected/ RFK Jr/ MMR vaccines/ DEI/ USAID and NIH funding complaints

19 februari | 23 min

Trump is breaking media brains / NIH cuts indirect payments and scientists freak out

19 februari | 27 min
Vad är en podd?

En liten tjänst av I'm With Friends. Finns även på engelska.

Podcastbild

00:00 -00:00
00:00 -00:00